Unfolding the long-term pathophysiological processes following an acute inflammatory demyelinating lesion of multiple sclerosis

Magnetic Resonance Imaging

Volumn 28, Issue 4, 2010, Pages 477-486

  Zaaraoui, Wafaa ^a   Rico, Audrey ^a,b   Audoin, Bertrand ^a,b   Reuter, Françoise ^a   Malikova, Irina ^a,b   Soulier, Elisabeth ^a   Viout, Patrick ^a   Le Fur, Yann ^a   Confort Gouny, Sylviane ^a   Cozzone, Patrick J ^a   Pelletier, Jean ^a,b   Ranjeva, Jean Philippe ^a  

^a University of Aix Marseille   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Brain; FMRI; Human; Inflammation; Magnetic resonance imaging; Magnetic resonance spectroscopy; Multiple sclerosis; Recovery

Indexed keywords

CHOLINE; CORTICOSTEROID; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CELL ACTIVATION; CLINICAL FEATURE; DEMYELINATING DISEASE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIA CELL; HEMIPLEGIA; HUMAN; IN VIVO STUDY; INFLAMMATORY DISEASE; LONGITUDINAL STUDY; METABOLIC DISORDER; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TISSUE REPAIR;

ACUTE DISEASE; ADULT; BRAIN; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS;

EID: 77952289454     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2009.12.011     Document Type: Article

References (40)

1. Miller D.H. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004, 1(2):284-294.
2. Zivadinov R., et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 2008, 255(Suppl 1):61-74.
3. Mezzapesa D.M., et al. Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. Hum Brain Mapp 2008, 29(5):562-573.
4. Ernst T., et al. Physiologic MRI of a tumefactive multiple sclerosis lesion. Neurology 1998, 51(5):1486-1488.
5. Law M., Meltzer D.E., Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 2002, 44(12):986-989.
6. Silver N.C., et al. Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion. J Neurol 1997, 244(3):204-207.
7. Tsui E.Y., et al. Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging. Comput Med Imaging Graph 2002, 26(5):343-346.
8. Brex P.A., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346(3):158-164.
9. Davie C.A., et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994, 117(Pt 1):49-58.
10. Filippi M., et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998, 43(6):809-814.
11. Rovira A., et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol 1999, 20(10):1939-1945.
12. Silver N.C., et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 2001, 248(3):215-224.
13. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
14. Frahm J., et al. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989, 11(1):47-63.
15. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987, 508:333-348.
16. Vanhamme L., van den Boogaart A., Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997, 129(1):35-43.
17. Audoin B., et al. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007, 13:41-51.
18. Confort-Gouny S., et al. A multiparametric data analysis showing the potential of localized proton MR spectroscopy in the brain in the metabolic characterization of neurological diseases. J Neurol Sci 1993, 118:123-133.
19. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452.
20. Barker P.B., Lin D.D.M. In vivo proton MR spectroscopy of the human brain. Prog Nucl Magn Reson Spectrosc 2006, (49):99-128.
21. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 2006, 22(4):235-244.
22. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991, 45(1):37-45.
23. Ross B., Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001, 265(2):54-84.
24. Cucurella M.G., et al. Serial proton spectroscopy, magnetization transfer ratio and T 2 relaxation in pseudotumoral demyelinating lesions. NMR Biomed 2002, 15(4):284-292.
25. De Stefano N., et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995, 38(6):901-909.
26. Reddy H., et al. Relating axonal injury to functional recovery in MS. Neurology 2000, 54(1):236-239.
27. Gass A., Niendorf T., Hirsch J.G. Acute and chronic changes of the apparent diffusion coefficient in neurological disorders - biophysical mechanisms and possible underlying histopathology. J Neurol Sci 2001, 186(Suppl 1):S15-S23.
28. McGowan J.C., et al. Magnetisation transfer imaging: theory and application to multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 64(Suppl 1):S66-S69.
29. Rocca M.A., et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005, 4(10):618-626.
30. Correale J., Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004, 251(11):1304-1316.
31. Narayana P.A. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005, 15(4 Suppl):46S-57S.
32. Schmierer K., et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004, 56(3):407-415.
33. Trebst C., et al. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008, 14(6):728-733.
34. Fitch M.T., Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008, 209(2):294-301.
35. Raivich G., Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 2004, 46(3):261-281.
36. Skaper S.D. The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 2007, 1122:23-34.
37. Loubinoux I., et al. Correlation between cerebral reorganization and motor recovery after subcortical infarcts. Neuroimage 2003, 20(4):2166-2180.
38. Mark V.W., et al. Constraint-induced movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findings. Mult Scler 2008, 14(7):992-994.
39. Widera D., et al. Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours?. J Cell Mol Med 2008, 12(2):459-470.
40. Jander S., Schroeter M., Saleh A. Imaging inflammation in acute brain ischemia. Stroke 2007, 38(2 Suppl):642-645.